Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Felodipine

FDA-approved product (tablet, extended release, oral), marketed as Felodipine, Plendil.

Registered studies
28
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Felodipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Diabetes mellitus
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

28registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Felodipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Felodipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    NCT07262710 · start 2025-12-01

    Registered record
    Registry ID
    NCT07262710
    Conditions
    Post-stroke Pneumonia
    Interventions
    angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-08-19
    Enrolment
    13,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-stroke Pneumonia
    Interventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension

    NCT06515678 · start 2024-05-20

    Registered record
    Registry ID
    NCT06515678
    Conditions
    Ovarian Cancer; Antiangiogenic-Associated Hypertension; Adjuvant Bevacizumab; Hypertension
    Interventions
    arm A - angiotensin converting enzyme inhibitors (ACEi); arm B - calcium channel blockers (CCBs); arm R - angiotensin receptor blockers ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-05-20
    Completion
    2024-08-31
    Enrolment
    9,464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Antiangiogenic-Associated Hypertension; Adjuvant Bevacizumab; Hypertension
    Interventionarm A - angiotensin converting enzyme inhibitors (ACEi); arm B - calcium channel blockers (CCBs); arm R - angiotensin receptor blockers ARB
    PhaseNot recorded
    Registry statusUnknown

  • Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study

    NCT05614037 · start 2022-10-28

    Registered record
    Registry ID
    NCT05614037
    Conditions
    Hypertension
    Interventions
    Felodipine sustained release tablets (trade name: plendil®); Felodipine Controlled Release Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-10-28
    Completion
    2023-03-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionFelodipine sustained release tablets (trade name: plendil®); Felodipine Controlled Release Tablets
    PhasePhase 1
    Registry statusUnknown

  • Coronavirus (COVID-19) ACEi/ARB Investigation

    NCT04330300 · start 2020-04-30

    Registered record
    Registry ID
    NCT04330300
    Conditions
    Hypertension; COVID-19
    Interventions
    Thiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2020-04-30
    Completion
    2021-12-01
    Enrolment
    2,414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID-19
    InterventionThiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    PhasePhase 4
    Registry statusSuspended

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Copenhagen Acute Renal Complications After Transplantations Study Group

    NCT02744872 · start 2013-09

    Registered record
    Registry ID
    NCT02744872
    Conditions
    Disorder Related to Lung Transplantation
    Interventions
    Felodipine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2016-10
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder Related to Lung Transplantation
    InterventionFelodipine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Coffee Interaction With the Antihypertensive Drug Felodipine

    NCT02232269 · start 2012-02

    Registered record
    Registry ID
    NCT02232269
    Conditions
    Food-Drug Interactions
    Interventions
    Black Coffee; Grapefruit Juice; Water; Felodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFood-Drug Interactions
    InterventionBlack Coffee; Grapefruit Juice; Water; Felodipine
    PhasePhase 1
    Registry statusCompleted

  • Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension

    NCT01520285 · start 2011-12

    Registered record
    Registry ID
    NCT01520285
    Conditions
    Hypertension
    Interventions
    Zanidip; Felodipine sustained-release tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-08
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionZanidip; Felodipine sustained-release tablet
    PhasePhase 4
    Registry statusCompleted

  • China Medical University Hospital (CMUH) Triapin Listing

    NCT00841880 · start 2009-01

    Registered record
    Registry ID
    NCT00841880
    Conditions
    Hypertension
    Interventions
    Ramipril + Felodipine; Ramipril; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-09
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionRamipril + Felodipine; Ramipril; Ramipril
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal

    NCT00905333 · start 2008-10

    Registered record
    Registry ID
    NCT00905333
    Conditions
    Healthy
    Interventions
    Candesartan (test); Felodipine (test); Candesartan Cilexetil; Felodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCandesartan (test); Felodipine (test); Candesartan Cilexetil; Felodipine
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions

    NCT02311530 · start 2008-10

    Registered record
    Registry ID
    NCT02311530
    Conditions
    Healthy
    Interventions
    Felodipine; Felodipine (Plendil®)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFelodipine; Felodipine (Plendil®)
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions

    NCT02327247 · start 2008-09

    Registered record
    Registry ID
    NCT02327247
    Conditions
    Healthy
    Interventions
    Felodipine; PLENDIL®
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFelodipine; PLENDIL®
    PhaseNot applicable
    Registry statusCompleted

  • Combined Antihypertensive Therapy and Sexual Dysfunction

    NCT01238705 · start 2008-04

    Registered record
    Registry ID
    NCT01238705
    Conditions
    Hypertension; Sexual Dysfunction
    Interventions
    Felodipine add Irbesartan; Felodipine add Metoprolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-04
    Completion
    2010-11
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Sexual Dysfunction
    InterventionFelodipine add Irbesartan; Felodipine add Metoprolol
    PhasePhase 4
    Registry statusUnknown

  • Role of AT1-receptor Blockers in Insulin-induced Vasodilation.

    NCT00742066 · start 2008-03

    Registered record
    Registry ID
    NCT00742066
    Conditions
    Hypertension; Insulin Resistance; Microcirculation
    Interventions
    Irbesartan; Felodipine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2009-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Insulin Resistance; Microcirculation
    InterventionIrbesartan; Felodipine; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Blood Pressure Lowering Effect of Transcutaneous Electrical Nerve Stimulation

    NCT01390701 · start 2008-01

    Registered record
    Registry ID
    NCT01390701
    Conditions
    Hypertension
    Interventions
    transcutaneous electrical nerve stimulation; felodipin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventiontranscutaneous electrical nerve stimulation; felodipin
    PhaseNot applicable
    Registry statusCompleted